Cargando…
Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.
The purpose of this study was to determine the safety, efficacy and impact on quality of life of recombinant human erythropoietin (r-HuEPO) for cancer patients undergoing radiotherapy (RT). An open-labelled randomized design was used, with patients randomized to either treatment or control arms. Pat...
Autores principales: | Sweeney, P. J., Nicolae, D., Ignacio, L., Chen, L., Roach, M., Wara, W., Marcus, K. C., Vijayakumar, S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150364/ https://www.ncbi.nlm.nih.gov/pubmed/9667681 |
Ejemplares similares
-
Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012) -
Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels
por: Ceelen, W, et al.
Publicado: (2007) -
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo
por: Christensen, Britt, et al.
Publicado: (2016) -
Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
por: Cascinu, S., et al.
Publicado: (1993) -
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)